(PHR) Phreesia - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US71944F1066
Stock:
Total Rating 20
Risk 39
Buy Signal -0.35
| Risk 5d forecast | |
|---|---|
| Volatility | 58.4% |
| Relative Tail Risk | -7.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.44 |
| Alpha | -72.72 |
| Character TTM | |
|---|---|
| Beta | 1.142 |
| Beta Downside | 0.671 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.40% |
| CAGR/Max DD | -0.44 |
EPS (Earnings per Share)
Revenue
Description: PHR Phreesia
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers an appointment scheduling system for online appointments, reminders, and referral tracking and management; registration solutions to automate patient self-registration; revenue cycle solutions that provide insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network solutions to deliver clinically relevant content to patients. It deploys its platform in a range of modalities, including Phreesia Mobile, a patients' mobile device; PhreesiaPads, a self-service intake tablets; Phreesia Dashboard, a web-based dashboard for healthcare services clients; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare services clients, including single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies, as well as government entities and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -5.38m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.08 > 1.0 |
| NWC/Revenue: 30.68% < 20% (prev 19.84%; Δ 10.84% < -1%) |
| CFO/TA 0.15 > 3% & CFO 61.4m > Net Income -5.38m |
| Net Debt (-102.9m) to EBITDA (26.4m): -3.89 < 3 |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.5m) vs 12m ago 6.22% < -2% |
| Gross Margin: 68.20% > 18% (prev 0.67%; Δ 6753 % > 0.5%) |
| Asset Turnover: 115.9% > 50% (prev 107.8%; Δ 8.09% > 0%) |
| Interest Coverage Ratio: -1.01 > 6 (EBITDA TTM 26.4m / Interest Expense TTM 2.24m) |
Altman Z'' -12.15
| A: 0.34 (Total Current Assets 240.9m - Total Current Liabilities 98.8m) / Total Assets 423.5m |
| B: -1.89 (Retained Earnings -800.5m / Total Assets 423.5m) |
| C: -0.01 (EBIT TTM -2.26m / Avg Total Assets 399.6m) |
| D: -7.76 (Book Value of Equity -800.2m / Total Liabilities 103.1m) |
| Altman-Z'' Score: -12.15 = D |
Beneish M -3.32
| DSRI: 0.80 (Receivables 88.3m/96.5m, Revenue 463.2m/405.1m) |
| GMI: 0.98 (GM 68.20% / 67.14%) |
| AQI: 0.90 (AQ_t 0.38 / AQ_t-1 0.42) |
| SGI: 1.14 (Revenue 463.2m / 405.1m) |
| TATA: -0.16 (NI -5.38m - CFO 61.4m) / TA 423.5m) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of PHR shares?
As of February 27, 2026, the stock is trading at USD 12.33 with a total of 1,030,675 shares traded.
Over the past week, the price has changed by -1.99%, over one month by -21.56%, over three months by -39.94% and over the past year by -54.33%.
Over the past week, the price has changed by -1.99%, over one month by -21.56%, over three months by -39.94% and over the past year by -54.33%.
Is PHR a buy, sell or hold?
Phreesia has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy PHR.
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.1 | 127.5% |
| Analysts Target Price | 28.1 | 127.5% |
PHR Fundamental Data Overview February 26, 2026
P/E Forward = 384.6154
P/S = 1.5176
P/B = 4.5923
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 600.1m USD (702.9m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 14.31x (Enterprise Value 600.1m / FCF TTM 41.9m)
FCF Yield = 6.99% (FCF TTM 41.9m / Enterprise Value 600.1m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 1.42 (Enterprise Value 600.1m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 10.16% (E(702.9m)/V(706.4m) * Re(10.11%) + D(3.48m)/V(706.4m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 10.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF] Terminal Value 61.16% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
[DCF] Fair Price = 4.68 (EV 179.4m - Net Debt -102.9m = Equity 282.3m / Shares 60.3m; r=10.16% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.22 | EPS CAGR: 139.3% | SUE: -0.29 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.35 | Chg7d=-0.001 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=7
EPS next Year (2027-01-31): EPS=1.50 | Chg7d=-0.003 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+28.8% | Growth Revenue=+15.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
P/S = 1.5176
P/B = 4.5923
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 600.1m USD (702.9m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 14.31x (Enterprise Value 600.1m / FCF TTM 41.9m)
FCF Yield = 6.99% (FCF TTM 41.9m / Enterprise Value 600.1m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 1.42 (Enterprise Value 600.1m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 10.16% (E(702.9m)/V(706.4m) * Re(10.11%) + D(3.48m)/V(706.4m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 10.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF] Terminal Value 61.16% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
[DCF] Fair Price = 4.68 (EV 179.4m - Net Debt -102.9m = Equity 282.3m / Shares 60.3m; r=10.16% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.22 | EPS CAGR: 139.3% | SUE: -0.29 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.35 | Chg7d=-0.001 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=7
EPS next Year (2027-01-31): EPS=1.50 | Chg7d=-0.003 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+28.8% | Growth Revenue=+15.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)